dabigatran and aspirin

Pharmacodynamic interaction: both drugs impair haemostasis through different pathways. Dabigatran is a direct thrombin inhibitor that prevents fibrin formation, while aspirin irreversibly inhibits cyclo-oxygenase-1, reducing thromboxane A2 and platelet aggregation. The combined effect is additive and results in a significantly increased risk of bleeding, especially from the gastrointestinal tract.

Co-administration of dabigatran and aspirin leads to a clinically important increase in bleeding risk, including major bleeding such as intracranial haemorrhage and gastrointestinal bleeding. This risk is further heightened in patients with additional risk factors, such as older age, renal impairment, or a history of bleeding. In some settings (e.g., after acute coronary syndrome or percutaneous coronary intervention), this combination may be used deliberately when the antithrombotic benefit outweighs the bleeding risk, but the risk remains substantial.

Prescribers should carefully assess the indication for combined therapy, weighing the reduction in thrombotic events against the increased bleeding risk. When the combination is considered necessary, use the lowest effective doses and monitor for signs of bleeding (e.g., haemoglobin, symptoms). Consider gastroprotection with a proton pump inhibitor, particularly in high-risk patients. Avoid concurrent use of additional antithrombotics unless there is a clear indication. Re-evaluate the need for continued combination therapy regularly.

This interaction is well established through pharmacological principles and supported by clinical outcome data from large randomised trials and meta-analyses. Current guidelines acknowledge the increased bleeding risk with the combination and provide specific recommendations for its management.